-selected autologous peripheral blood stem cell transplantation in a patient with subcutaneous panniculitic T cell lymphoma (SPTCL) transformed into leukemia Subcutaneous panniculitic T cell lymphoma (SPTCL) is an unusual variant of peripheral T cell lymphoma (PTCL) in which the malignant infiltrate preferentially involves the subcutaneous fatty tissue, this event often has an aggressive course and is rapidly fatal, despite combination chemotherapy and/or radiation therapy. Morbidity and mortality of SPTCL is usually not due to disseminated lymphoma with organ failure. Rather it is due to complications of cytopenias associated with the hemophagocytic syndrome (HPS). 1 However, we report a case that could be a rare type of SPTCLs, because there was no evidence of the HPS that is usually associated with a poor outcome, and in fact a leukemic relapse. We describe here the clinical features in a young man with SPTCL originating on the right cheek, which transformed into leukemia at the time of the first relapse. Treatment, which included CD34 + -selected autologous peripheral blood stem cell transplantation (CD34 + -APBSCT), using TBI/CY/VP-16 as a conditioning regimen, was effective.
In December 1995, a 21-year-old Japanese man had a small, non-tender subcutaneous nodule on his right cheek. On admission to the Hospital of Hokkaido University School of Medicine in April 1996, he was not febrile and there was no lymphadenopathy. Skin biopsy of the lesion demonstrated atypical lymphocytes infiltrating subcutaneous fatty tissue, and revealed diffuse medium-sized cell lymphoma. Immunohistochemical studies showed that the atypical lymphocytes were positive for CD45RO, LCA, negative for CD20, MT-1 and MB-1, and showed a predominantly T cell profile. However, Southern blot analysis did not reveal clonality for either the T cell receptor (TCR) ␤ or the ␥ chain gene rearrangement. Clinical complete remission (CCR) was attained after six cycles of CHOP, and local irradiation was given to the right cheek (40 Gy/16 fractions). In November 1997, however, he complained of excessive fatigue for the past several weeks, intermittent low-grade fever, and a modest weight loss. Physical examination revealed lymphadenopathy and hepatosplenomegaly. Blood examination showed hemoglobin of 10 g/dl, white cell count of 6.9 × 10 9 /l with 26% neutrophils, 62% lymphocytes, 2% monocytes, 10% atypical lymphocytes, and platelet count of 3.6 × 10 9 /l. The coagulation test was within normal limits. Serum LDH was elevated to 781 IU/l, but soluble interleukin-2-receptor (sIL2-R) was normal. Biopsy of neck lymph nodes and bone marrow gave identical pathological and immunohistochemical findings as the first skin lesion, and his tumor cells were positive for only CD4 antigen. Again, Southern blot analysis did not reveal clonality for TCR gene rearrangement, nor immunoglobulin heavy (IgH) and lightchain (IgL) gene rearrangement in his peripheral blood, bone marrow, and neck lymph nodes. The diagnosis at first relapse of SPTCL with transformation into leukemia was made. Therefore, combination chemotherapy, an induction regimen for ALL, 3 4 During hematopoietic recovery after the first course of VIP-E therapy, PBSC were harvested by continuous leukapheresis, and CD34
+ cells were positively immunoselected, using the method described elsewhere. 5 The overall recovery of CD34 + cells was 33.3% with a purity of 97.6% and the purified CD34 + cells numbered 2.19 × 10 6 /kg. The CD4 + cells which were positive for the lymphoma cells comprised 0.04%. After the three cycles of VIP-E, he remained in CCR. The conditioning regimen given was etoposide (750 mg/m 2 day −7 to day −6) and cyclophosphamide (60 mg/kg day −5 to day −4) and total body irradiation (TBI: 12 Gy, two daily fractions from day −3 to day −1). This was started on 2 April 1998, and CD34 + -selected PBSC were re-infused on 9 April 1998 (day 0). Cells infused included 2.19 × 10 6 /kg CD34 + cells, 3.15 × 10 5 /kg CFU-GM. G-CSF (5 g/kg subcutaneously) was administered from day 1 until the time of granulocyte recovery. After PBSCT, the time required to recover neutrophils over 0.5 × 10 9 /l and platelets over 50 × 10 9 /l was 15 days and 20 days, respectively. On day 55, he had an elevated body temperature, headache, and blood examination revealed pancytopenia. Lumbar puncture was done and the cerebrospinal fluid showed a slight increase of the number of mononuclear cells without atypical features. Virus and bacteria were not evident in cultures. The diagnosis of aseptic meningitis was made. Clinical symptoms resolved within 10 days without drug treatments. No other complications occurred in the clinical course. He was discharged on day 77, and has remained in CCR for 14 months after CD34
+ -selected APBSCT. No maintenance chemotherapy has been required. To date, there are a few reports of effective treatment of patients with SPTCL by high-dose chemotherapy following stem cell transplantation. Koizumi et al 6 reported effective treatment which included APBSCT for a young man with SPTCL but he had no bone marrow infiltration by lymphoma cells. Claire et al 7 described a patient with subcutaneous T cell lymphoma who was treated with systemic treatment of chemotherapy, autologous stem cell support, and amputation of the limb involved with the lymphomatous infiltrate. Mehregan et al 8 described a patient with bone marrow involvement with lymphoma at the time of relapse. Moreover, Romero et al 9 reported that a patient succumbed to disseminated leukemia. In both cases, death was not caused by complications of the HPS. HPS was not observed in our patient. However, bone marrow involvement by lymphoma cells was present at first relapse, possible evidence of a prognostic marker, indicating the need for expedient and aggressive therapy. Tumor cells in our patient did not express the CD34 antigen (0.4%) and the prognosis was poor because of transformation into leukemia at first relapse. Therefore, we prescribed CD34
+ -APBSCT. Southern blot analysis did not reveal clonality for the TCR gene rearrangement in peripheral blood, bone marrow, and neck lymph nodes at relapse, as well as original tumor. Indeed, in a revised European-American classification of lymphoid neoplasms (REAL), 10 it is mentioned that TCR genes are not always rearranged in PTCL. Willemze et al 11 reported that clonal rearrangement of TCR gene is found in at least 50% of SPTCLs. Therefore, we could not examine the possibility of residual tumor cells among the purified cells with molecular methods. The purity of selected CD34
+ cells was high (97.5%) and the rate of CD4 which was a marker of his tumor cells was very low (0.04%). Thus, we were convinced that a considerable number of tumor cells in the apheresis products had been purged. Sharp et al 12 described that a relatively good outcome can be achieved with high-dose chemotherapy and PBSCT, even in patients with significant marrow tumor burden. Based on the experience in acute leukemia, the combination of fractionated total-body irradiation (FTBI) and cyclophosphamide has been widely used as a preparatory regimen. 13 Our patient is a young man with SPTCL which transformed into leukemia at first relapse, with poor prognosis. Allogeneic bone marrow transplantation was ruled out as no HLA-matched donor was available. Therefore, to enhance the antitumor effect of the myeloablative regimen in poor-risk lymphoid malignancies, and to reduce the quantity of contaminating tumor cells in apheresis products, we prescribed TBI, etoposide, and cyclophosphamide followed by CD34 + -selected APBSCT.
14 This treatment proved to be effective and he has remained in CCR for 14 months after CD34 + -APBSCT, at the time of writing.
In conclusion, TBI/CY/VP-16 followed by CD34 + -APBSCT can be one of the most effective therapies for patients with SPTCL. 
